Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 8000 participants.

Also called NCT05688579

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 8,000 participants (planned count) (from the registry)
Sponsor
Nanfang Li (from the registry)
Registry
  • NCT NCT05688579
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT05688579. Randomized; single masking; primary purpose prevention. Start 2023-04-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
Acronym
EMRACHH
Condition
Hypertension
Condition
Hyperaldosteronaemia
Intervention (Other)
Blank control
Lead sponsor
Nanfang Li (class: other)

Record details

Record id
cardio:ct-nct05688579
Content hash
1b3bbd6984457a0247cbb4a4cbc53d430b29f98f28fc2b358eaeaf27c3631aef